Home
About
Capabilities
R&D
Investors
News
Careers
中文
Home
About
Capabilities
R & D
Investors
News
Careers
Press Release
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
Jun 14, 2023
Mabwell Announces the U.S. FDA approval of 9MW3811 for IND
➞
Jun 11, 2023
Launch Conference of MAILISHU, World's Second Prolia® Biosimilar, Held Successfully
➞
May 24, 2023
Mabwell announces NMPA approval of 9MW3811 for IND
➞
May 22, 2023
Mabwell Publishes the Preclinical Study Results on Its Nectin-4 Targeting ADC in A Well-known AACR Journal
➞
May 10, 2023
Clinical Trial Application for 7MW3711 - an Innovative Drug Developed by Mabwell's ADC Platform, Accepted by NMPA
➞
Apr 26, 2023
Mabwell's First Self-commercialized Drug Reached its National Logistics Ceremony
➞
Apr 05, 2023
China’s First Nectin-4 Targeted ADC Drug 9MW2821 Clinical Progress Released
➞
Mar 31, 2023
The World's Second Approved Biosimilars of Denosumab (MAILISHU)
➞
Mar 16, 2023
Mabwell's Clinical Trial Application for 9MW3811 Accepted by NMPA
➞
Mar 13, 2023
Mabwell Launched First in human Clinical Trial of Its Iron Homeostasis Regulating Macromolecular Drug 9MW3011
➞
上一页
1
2
3
4
下一页